We are pleased to launch the COALA Scientific Webinar Series with this first session, organized by Work Package 1 (WP1). The webinar is free (upon registration) and open to everyone, whether or not they belong to the COALA consortium.

📅 Date & Time: 12 March 2026, 12:30–13:00 CET

🧬 Webinar Title
Minimal Residual Disease (MRD) as a therapeutic guide in oncogene-addicted lung adenocarcinoma: where do we stand and how can we improve?

✅ Register now to receive the Teams link : registration 

🎤 Speaker
Célia Delahaye, PhD – Centre de Recherches en Cancérologie de Toulouse (CRCT)

🎙 Moderation
Aurélie Swalduz & Olivier Calvayrac (WP1 Leaders)

⏱ Webinar Structure
• Presentation — 20 minutes
• Discussion & Q&A — 10 minutes

🔬 Description
Targeted therapies have revolutionized the standard of care for patients with lung cancer harboring activating driver alterations such as EGFR, ALK, ROS1, or BRAF. Despite impressive initial responses, relapse remains frequent, underscoring the persistence of residual disease.
The assessment of minimal residual disease (MRD), particularly through liquid biopsy approaches including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), represents a promising strategy to predict response, detect molecular relapse, and better inform therapeutic decisions.
What do we know about MRD, where do we currently stand in integrating MRD into clinical practice, and how can we more effectively leverage its potential to improve patient outcomes?

📡 Live broadcast & replay available